Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010
Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008
The stimulator of soluble guanylate cyclase riociguat protects against bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011
A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 874-880 Year: 2012
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Soluble guanylate cyclase stimulator riociguat prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Source: Annual Congress 2011 - Translational models of disease Year: 2011
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017
Soluble guanylyl cyclase expression is reduced in acute lung injury Source: Eur Respir J 2006; 28: Suppl. 50, 398s Year: 2006
The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Source: Eur Respir Rev 2007; 16: 105-112 Year: 2007
The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013